| The cost-effectiveness of prenatal screening for spinal muscular atrophy. | |
| | |
MedLine Citation:
|
PMID: 20207244 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We sought to investigate the cost-effectiveness of prenatal screening for spinal muscular atrophy (SMA). STUDY DESIGN: A decision analytic model was created to compare a policy of universal SMA screening to that of no screening. The primary outcome was incremental cost per maternal quality-adjusted life year. Probabilities, costs, and outcomes were estimated through literature review. Univariate and multivariate sensitivity analyses were performed to test the robustness of our model to changes in baseline assumptions. RESULTS: Universal screening for SMA is not cost-effective at $4.9 million per quality-adjusted life year. In all, 12,500 women need to be screened to prevent 1 case of SMA, at a cost of $5.0 million per case averted. Our results were most sensitive to the baseline prevalence of disease. CONCLUSION: Universal prenatal screening for SMA is not cost-effective. For populations at high risk, such as those with a family history, SMA testing may be a cost-effective strategy. |
| | |
Authors:
|
Sarah E Little; Vanitha Janakiraman; Anjali Kaimal; Thomas Musci; Jeffrey Ecker; Aaron B Caughey |
Related Documents
:
|
16116514 - Screening for primary open-angle glaucoma in the developed world: are we there yet? 655064 - Scoliosis and school screening for spinal deformity. 16150014 - Informing parents about newborn screening. 1647744 - Establishment of an oocyte donor program. donor screening and selection. 19625864 - A web-based videoconferencing approach to training caregivers in rural areas to compens... 15789994 - Reflective practice: a meaningful task for students. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of obstetrics and gynecology Volume: 202 ISSN: 1097-6868 ISO Abbreviation: Am. J. Obstet. Gynecol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-08 Completed Date: 2010-04-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370476 Medline TA: Am J Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 253.e1-7 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2010 Mosby, Inc. All rights reserved. |
Affiliation:
|
Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost-Benefit Analysis Decision Support Techniques* Female Genetic Testing / economics* Heterozygote Detection Humans Pregnancy Prenatal Diagnosis* Quality-Adjusted Life Years Spinal Muscular Atrophies of Childhood / diagnosis*, genetics Survival of Motor Neuron 1 Protein / genetics |
| Chemical | |
Reg. No./Substance:
|
0/SMN1 protein, human; 0/Survival of Motor Neuron 1 Protein |
| Comments/Corrections | |
Comment In:
|
Am J Obstet Gynecol. 2010 Mar;202(3):209-11
[PMID:
20207235
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neonatal outcome following elective cesarean section beyond 37 weeks of gestation: a 7-year retrospe...
Next Document: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia.